New pill plus immunotherapy targets Hard-to-Treat cancers
NCT ID NCT07446049
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two drugs—CVL237 tablets and serplulimab injection—in people with advanced solid tumors that have lost or have low levels of a protein called PTEN. The trial aims to find the safest dose and see if the combo can shrink tumors or delay their growth. About 180 adults aged 18 to 75 with various cancers (like gastric, lung, or breast) who have not responded to standard treatments will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CVL237 tablets and serplulimab injection
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced solid tumors that have a specific genetic change (PTEN loss), potentially slowing disease progression.
What could go wrong
This is an early-phase trial (Phase Ib/II) with only 180 participants, so results may not apply to everyone. The combination may cause side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.